TP53 and cancer: Overall, the above data suggests that TP53 functionality should be considered when matching drugs to cancer patients based on the various driver gene mutations in their tumor, and that this TP53 functional status should preferentially be estimated via a phenocopying score rather than TP53 gene mutations.